Equities

Vistin Pharma ASA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Vistin Pharma ASA

Actions
  • Price (EUR)1.84
  • Today's Change-0.02 / -1.08%
  • Shares traded1.03k
  • 1 Year change-8.46%
  • Beta0.8131
Data delayed at least 15 minutes, as of Feb 17 2026 07:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of NOK
(except for per share items)
Fiscal data as of Dec 31 2025202520242023
ASSETS
Cash And Short Term Investments161326
Total Receivables, Net1055260
Total Inventory827780
Prepaid expenses--1.752.81
Other current assets, total0.00----
Total current assets204143169
Property, plant & equipment, net224230220
Goodwill, net------
Intangibles, net------
Long term investments1212--
Note receivable - long term------
Other long term assets0----
Total assets439385403
LIABILITIES
Accounts payable301319
Accrued expenses------
Notes payable/short-term debt--00
Current portion long-term debt/capital leases--0.9251
Other current liabilities, total49500.00
Total current liabilities796469
Total long term debt--1.330
Total debt--2.2451
Deferred income tax253.52--
Minority interest------
Other liabilities, total7.036.6011
Total liabilities1117581
SHAREHOLDERS EQUITY
Common stock444444
Additional paid-in capital74129207
Retained earnings (accumulated deficit)21113672
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity329310323
Total liabilities & shareholders' equity439385403
Total common shares outstanding444444
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.